CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-05-09 | Bridger Gary Director | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-03-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +1,289 | $7.70 | $10K | 790,130 |
| 2016-03-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +11,840 | $7.70 | $91K | 6,613,731 |
| 2016-03-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +20,192 | $7.91 | $160K | 810,322 |
| 2016-03-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +185,413 | $7.91 | $1.5M | 6,799,144 |
| 2016-03-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +14,046 | $8.16 | $115K | 824,368 |
| 2016-03-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +128,975 | $8.16 | $1.1M | 6,928,119 |
| 2016-03-15 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +3,374 | $7.88 | $27K | 781,421 |
| 2016-03-15 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +30,986 | $7.88 | $244K | 6,533,759 |
| 2016-03-15 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +7,420 | $8.03 | $60K | 788,841 |
| 2016-03-15 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +68,132 | $8.03 | $547K | 6,601,891 |
| 2016-03-10 | SHREWSBURY STEPHEN B CMO; Senior VP Clinical Dev. | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2016-03-10 | Mitchell David Chilton VP Global Regulatory & Quality | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2016-03-10 | Main David President and CEO | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2016-03-10 | MacKenzie Lloyd VP Technical Operations | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2016-03-10 | Alam Kamran CFO, Vice President Finance | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2016-01-26 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +7,318 | $10.80 | $79K | 777,652 |
| 2016-01-26 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +66,345 | $10.80 | $717K | 6,499,192 |
| 2016-01-26 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +395 | $11.00 | $4K | 778,047 |
| 2016-01-26 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +3,581 | $11.00 | $39K | 6,502,773 |
Page 17 of 20 · 397 trades